DV
Dividend Vision

CADL — Candel Therapeutics, Inc.

Candel Therapeutics, Inc. (CADL)

Total return is 67.4% over the past 5 years, 21.8 points behind SPY at 89.2%. Its deepest 1-year drawdown was 32.5%.

CADL appears to be a single-stock equity position rather than a diversified ETF, holding shares of Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company. As a biotech stock with no current dividend distribution, it does not generate ongoing income and carries the concentration risk and volatility typical of individual therapeutic development companies. This holding appeals primarily to growth-oriented investors seeking exposure to emerging biotechnology rather than dividend or income-focused investors.

CADL key facts

Asset type
Stock
Asset class
Equity
Inception date
07/27/2021
Distribution frequency
None
Last close
$11.72
Market cap
$902,919,104
Average volume
2069292.0
Beta
-0.502
Payout ratio
0.0
Forward P/E
43.4783
EPS
$-1.12